The Europe Pyrogen Testing Market was worth $147.40 million in 2015 and estimated to be growing at a CAGR of 12.4%, to reach $ 264.44 million by 2020. Pyrogens are substances produced by bacterium, when released into blood produces fever. Pyrogen testing is used for ensure these toxic substances are absent in the body.
Pyrogen contamination can be caused due to various reasons such as environmental factors, through contaminated solute, solvent, container and apparatus. When contaminated drugs are injected into the blood stream the toxins bypass normal defence mechanism to overcome these white blood cells in the body start releasing another form of pyrogen causing high fever which in some cases may even lead to shock and death
European market for Pyrogen testing is expected to show significant growth due to increasing number of biologic products. Rise in number of chronic diseases, intensifying importance on Research and development are some of the key driving factors for market growth. However complex regulatory policies and unclear reimbursement issues are some of the factors restraining the growth of the market.
Europe pyrogen testing market is segmented into product, application and test type. Based on product the market is further analyzed as Kits & Reagents, Services and Instruments. On the basis of application the market is segmented as Pharmaceutical and Biological Manufacturing, Medical Device Manufacturing and other applications. By test type pyrogen testing market is segmented into LAL tests, In-Vitro Tests and Rabbit Tests. LAL tests are further sub segmented into Chromogenic Tests, Turbidimetric Tests and Gel Clot tests.
Based on geography Europe pyrogen testing market is analyzed under various regions namely United Kingdom, Germany, France, Italy and Spain. Europe is the second largest market for pyrogen testing accounting for a share of approximately XX%. Within Europe, United Kingdom is the largest market accounting for a share of approximately XX% whereas Germany is estimated to be the fastest growing due to increasing number of chronic diseases.
Some of the major companies discussed in the report are Associates of Cape Cod, Inc., Lonza Group, Merck Kga, Ellab A/S, Genscript, Hyglos GmbH, Thermo Fisher Scientific, Inc., Charles River Laboratories, Inc., Wako Chemicals Usa, Inc. and WUXI Pharmatech (Cayman) Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.1.1 Kits and Reagents
5.1.2 Services
5.1.3 Instruments
5.2 By Application
5.2.1 Pharmaceutical and Biological Manufacturing
5.2.2 Medical Device Manufacturing
5.2.3 Other Applications
5.3 By Test Type
5.3.1 LAL Tests
5.3.1.1 Chromogenic Tests
5.3.1.2 Turbidimetric Tests
5.3.1.3 Gel Clot Tests
5.3.2 In-Vitro Tests
5.3.3 Rabbit Tests
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Associates of Cape Cod, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Charles River Laboratories, Inc.
8.3 Lonza Group
8.4 Merck Kgaa
8.5 Ellab A/S
8.6 Genscript
8.7 Hyglos GmbH
8.8 Thermo Fisher Scientific, Inc.
8.9 Wako Chemicals USA, Inc.
8.10 WUXI Pharmatech (Cayman) Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
